<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412917</url>
  </required_header>
  <id_info>
    <org_study_id>CTRV-FV-2-007</org_study_id>
    <nct_id>NCT02412917</nct_id>
  </id_info>
  <brief_title>A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ContraVir Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ContraVir Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel-group, active controlled
      comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus
      valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel-group, active controlled
      comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus
      valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).
      Subjects diagnosed with uncomplicated AHZ within 72 hours of lesion appearance and worst pain
      of 4 or greater at day 1, will be randomized (1:1:1) to one of three treatment groups and
      will begin study treatment at the Day 1 visit(within 72 hours of AHZ lesion appearance) to
      either: 1. FV-100 400mg QD, 2. FV-100 400mg BID(total daily dose of 800mg), or 3.
      Valacyclovir 1000mg 3 times a day for a total daily dose of 3000mg. Subjects will be
      monitored for adverse events through day 21. Efficacy assessments for lesion status and AHZ
      pain are captured til day 120.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of post-herpetic neuralgia(PHN) following treatment with 2 dose regimens of FV-100 compared to valacyclovir.</measure>
    <time_frame>Day 1 to Day 120</time_frame>
    <description>efficacy measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute herpes zoster associated pain, as measured by Zoster Brief Pain Inventory(ZBPI)</measure>
    <time_frame>Day 1 to Day 120</time_frame>
    <description>efficacy measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on lesion formation and healing of 2 dose regimens of FV-100 compared to valacyclovir</measure>
    <time_frame>Day 1 to Day 120</time_frame>
    <description>efficacy measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and classification of adverse events in 2 dosing regimens of FV-100</measure>
    <time_frame>Day 1 to Day 120</time_frame>
    <description>Safety measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic profile of the active metabolite of FV-100 after 7 days of dosing at 400mg QD versus compared with 400mg BID</measure>
    <time_frame>Day 1 to Day 120</time_frame>
    <description>Pharmacokinetic</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">237</enrollment>
  <condition>Shingles</condition>
  <condition>Herpes Zoster</condition>
  <condition>Postherpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>FV-100 400 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FV-100 400mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FV-100 400mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FV-100 400mg BID(total daily dose of 800mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>valacyclovir 1000mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FV-100</intervention_name>
    <description>antiviral nucleoside analog</description>
    <arm_group_label>FV-100 400 mg QD</arm_group_label>
    <arm_group_label>FV-100 400mg BID</arm_group_label>
    <other_name>antiviral nucleoside analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>antiviral nucleoside analog</description>
    <arm_group_label>valacyclovir</arm_group_label>
    <other_name>valtrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receive a clinical diagnosis of uncomplicated AHZ as evidenced by a unilateral
             dermatomal rash

          -  Have zoster-related pain

          -  Are able to be randomized and receive their first dose within approximately 120 hours
             from appearance of rash

        Exclusion Criteria:

          -  Have multidermal or disseminated AHZ

          -  Have facial, ophthalmologic or oral manifestations

          -  Have received Zostavax
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Sullivan-Bolyai</last_name>
    <role>Study Director</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TX</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

